Imipramine linked to lower death risk in Alzheimer’s patients
An observational analysis linked imipramine prescriptions to lower mortality over 10 years in Alzheimer’s patients compared with other antidepressants or none.
Our read
Interventions- Studied:
- Preprint: cohort study of people with Alzheimer’s disease, against other antidepressant users or nonusers
- What changed:
- People prescribed imipramine had fewer deaths from any cause over 10 years than those prescribed other antidepressants or none
- The catch:
- Health or care differences between prescription groups could explain the mortality association
- In the record:
- One of 6 papers on imipramine on record: 1 with results in people, 3 in animals.
- Why it’s aging research:
- It measures how long life or healthy life lasts.
Editor of record: Boris Djordjevic · AgingResearch.News
People with Alzheimer’s disease who were prescribed imipramine, an antidepressant, had fewer deaths from any cause over 10 years in an observational analysis of the National Alzheimer’s Coordinating Center’s database. Comparison groups included people prescribed other drugs in the same antidepressant class, other antidepressant classes, or no antidepressants.
Separate laboratory experiments found that imipramine bound to amyloid-beta, a protein fragment involved in Alzheimer’s disease. In Alzheimer’s brain organoids—simplified brain-like structures grown from human stem cells—the drug reduced amyloid-beta buildup and nerve-cell loss. These laboratory results were distinct from the mortality association observed in people.
Why it matters
For Alzheimer’s care, the authors called for prospective trials to test whether imipramine could improve cognition and reduce mortality.
Caveats
People prescribed imipramine may have differed in health or care from the comparison groups. The abstract gives no patient count or size of the mortality association, and the preprint has not been peer-reviewed.
The paper
Imipramine binds to amyloid-β and extends the survival of Alzheimer's disease patients
University of Colorado System
bioRxiv, Nov 3, 2026, Open access, Preprint, not yet peer-reviewed
Comments
Be the first to comment.